Eliminating the benzos: A benzodiazepine-sparing approach to preventing and treating alcohol withdrawal syndrome
- PMID: 37934662
- DOI: 10.1097/TA.0000000000004188
Eliminating the benzos: A benzodiazepine-sparing approach to preventing and treating alcohol withdrawal syndrome
Abstract
Background: Alcohol withdrawal syndrome (AWS) represents significant cost to the hospitalized trauma population from a clinical and financial perspective. Historically, AWS has been managed with benzodiazepines. Despite their efficacy, benzodiazepines carry a heavy adverse effect profile. Recently, benzodiazepine-sparing protocols for the prophylaxis and treatment of AWS have been used in medical patient populations. Most existing benzodiazepine-sparing protocols use phenobarbital, while ours primarily uses gabapentin and clonidine, and no such protocol has been developed and examined for safety and efficacy specifically within a trauma population.
Methods: In December of 2019, we implemented our benzodiazepine-sparing protocol for trauma patients identified at risk for alcohol withdrawal on admission. Trauma patients at risk for AWS admitted to an academic Level 1 trauma center before (conventional) and after (benzodiazepine-sparing [BS]) protocol implementation were compared. Outcomes examined include morphine milligram equivalent dosing rates and lorazepam equivalent dosing rates as well as the Clinical Institute Withdrawal Assessment for Alcohol, revised (CIWA-Ar) scores, hospital length of stay, intensive care unit length of stay, and ventilator days.
Results: A total of 387 conventional and 134 benzodiazepine sparing patients were compared. Injury Severity Score (13 vs. 16, p = 0.10) and admission alcohol levels (99 vs. 149, p = 0.06) were similar. Patients in the BS pathway had a lower maximum daily CIWA-Ar (2.7 vs. 1.5, p = 0.04). While mean morphine milligram equivalent per day was not different between groups (31.5 vs. 33.6, p = 0.49), mean lorazepam equivalents per day was significantly lower in the BS group (1.1 vs. 0.2, p < 0.01). Length of stay and vent days were not different between the groups.
Conclusion: Implementation of a benzodiazepine-sparing pathway that uses primarily clonidine and gabapentin to prevent and treat alcohol withdrawal syndrome in trauma patients is safe, reduces the daily maximum CIWA-Ar, and significantly decreases the need for benzodiazepines. Future studies will focus on outcomes affected by avoiding AWS and benzodiazepines in the trauma population.
Level of evidence: Therapeutic/Care Management; Level IV.
Copyright © 2023 American Association for the Surgery of Trauma.
References
-
- Ng C, Fleury M, Hakmi H, Bronson B, Vosswinkel JA, Huang EC, et al. The impact of alcohol use and withdrawal on trauma outcomes: a case control study. Am J Surg . 2021;222(2):438–445.
-
- Bard MR, Goettler CE, Toschlog EA, Sagraves SG, Schenarts PJ, Newell MA, et al. Alcohol withdrawal syndrome: turning minor injuries into a major problem. J Trauma . 2006;61(6):1441–1445 discussion 1445-6.
-
- Jawa RS, Stothert JC, Shostrom VK, Yetter DL, Templin HR, Cemaj SK, et al. Alcohol withdrawal syndrome in admitted trauma patients. Am J Surg . 2014;208(5):781–787.
-
- Ahmed N, Kuo Y. Alcohol withdrawal syndrome in trauma victims. Under appreciated costly event. Am J Surg . 2021;222(3):506–507.
-
- Seshadri A, Appelbaum R, Carmichael SP 2nd, Farrell MS, Filiberto DM, Jawa R, Kodadek L, Mandell S, Miles MVP, Paul J, Robinson B, Michetti CP. Prevention of alcohol withdrawal syndrome in the surgical ICU: an American Association for the Surgery of Trauma Critical Care Committee Clinical Consensus Document. Trauma Surg Acute Care Open . 2022;7(1):e001010.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials